Dr. Mikhail Blagosklonny: Revolutionary Aging Doctor

Dr. Mikhail Blagoskloony is a scientist who studies aging and cancer. He earned his M.D in internal medicine and his PhD in external medicine from the First Pavlov State Medical University of St. Petersburg. In 2002, he was appointed associate professor of medicine at New Your Medical College. Shortly thereafter he accepted a position as senior scientist at Ordway Research Institute. Since 2009 Dr. Mikhail Blagoskloony is working as a professor of Oncology at Roswell Park Cancer Institute in New York. View his LinkedIn profile

Dr. Blagoskloony formulated a hypothesis about the possible role of TOR (Target of rapamycin) signaling in aging and cancer by the use of rapamcyin, a cancer drug as a possible treatment for life extension. In on words, it would be an anti-aging drug that would slow or reverse aging. While Dr. Blagoskloony was working on cancer patients, he realized that the same qualities that made rapamycin effective at slowing tumor growth, would possibly slow aging as well. In fact the doctor even takes rapamcyin himself.

His role as professor of Oncology at Roswell Park Cancer Institute in New York is to help facilitate the development of new anti-cancer strategies and development and methods of cancer protection that are not limited to: therapy, selective combination anticancer drugs, and prevention of cancer by slowing down organismal aging. of In addition to Mikhail Blagoskloony’s groundbreaking work in his field he is Founding Editor and Editor-in-Chief for Cell Cycle and Associate Editor of the following publications: PLOS ONE, Cancer Biology & Therapy, American Journal of Pathology, Cell Death & Differentiation, Autophagy, Cancer Research, and International Journal of Cancer. Follow Mikhail on Loop


Seattle Genetics’ Strategic Plans for New Cancer Drugs and Expanding its Workforce

Seattle Genetics recently released a cancer drug, Adcetris, its first approved drug. The company, as an established cancer research center, is trying to increase the usage of the drug. According to a statement released by Seattle Genetics’ CEO Clay Siegall, Adcetris is currently being tested in over 70 clinical trials. The experiments mainly focus on the different types of lymphomas disease. The company also announced that a third phase clinical trial is being conducted for Hodgkin lymphoma. Dr. Siegall pointed out that the trial will impact primarily on the cancer-oriented medical initiatives undertaken by his company.

The Current and Projected Commercial Performance of Adcetris

Adcetris has amassed over $226 in the US and Canadian markets in the last one year. Seattle Genetics projects the sales to range between $255 and $275 million in 2016. In partnership with Takeda Pharmaceuticals, the company currently sells the cancer drug to patients and medical facilities outside North America.

Other Drugs Developed by Seattle Genetics

Seattle Genetics has 12 drugs in its cancer drugs roster excluding Adcetris. A new drug, known as 33A, is still in the 3rd phase of its clinical trial. The drug was developed to treat acute cases of myeloid leukemia. The company has also developed two bladder cancer drugs and one for breast cancer. Dr. Siegall said that relevant details regarding these three drugs would be released before the end of 2016.

Job Opportunities

Besides developing several cancer drugs, Seattle Genetics is also planning to hire 100 employees who will work in its U.S. headquarters. The company is also planning to hire 20 employees who will be based in its Switzerland branch. Seattle currently comprises of over 800 employees.

Clay Siegall

Dr. Siegall is the current president and chief executive officer of Seattle Genetics. He co-founded the company in 1998, and he serves as the chair of its board of directors to date. He served at Ultragenyx in 2014 as a board member.

Dr. Siegall has worked for the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Institute of Health as well as the National Cancer Institute. He graduated from the University of Maryland with a B.S in Zoology and George Washington University with a Ph.D. in Genetics.

Seattle Genetics Advancing Cancer Treatments through Engineered Monoclonal Antibodies

Chemotherapy drugs interfere with the rapidly growing cells of the body. It affects cells like those of the stomach lining, skin, hair and fingernails. This is why chemotherapy causes temporary side effects (late effects) to patients. The late effects differ from patient to patient depending on the type of medicines used. New therapeutic treatments have been designed to treat cancer by targeting malignant cells, reducing damage to normal tissues and reducing the toxic effects of traditional chemotherapy.

Seattle Genetics is a biotechnology company that aims at revolutionizing the treatment of cancer by developing engineered monoclonal antibodies. The company is a leading developer of antibody-drug conjugates (ADCs). The technology has resulted in therapies that are better tolerated and can be used with chemotherapy to improve patient outcomes without a considerable increase in toxicities.

Clay Siegall has produced the first product in the new class of ADCs. The product is known as ADCETRIS® (brentuximab vedotin) and was approved by the FDA in 2011. Seattle Genetics is further expanding the ADCETRIS opportunity by carrying out an extensive clinical development program to evaluate the drug’s potential in treating CD30-expressing lymphomas. Besides ADCETRIS, the company has a broad pipeline to address various types of cancers like colon cancer, leukemia, solid tumors, and breast cancer among others.

Seattle Genetics was founded in 1977 by Dr. Clay Siegall and Dr. H. Perry Fell. Dr. Siegall is a scientist by profession and has almost 20 years of experience in therapeutic drug treatment and cancer research. Before co-founding the biotechnology company, Dr. Siegall worked with the Bristol-Myers Squibb Pharmaceutical Research Institute as a senior research investigator from 1991 and 1995 and a chief scientist from 1995 to 1997. He served as a staff fellow and biotechnology fellow at the National Cancer Institute, and National Institutes of Health from 1988 to 1991.

Clay Siegall has enabled Seattle Genetics to achieve most of its goals. The achievements include initiating clinical trials of SGN-15 and entering into partnership agreements with numerous biotechnology and pharmaceutical companies. The partnerships have been vital in expanding the company’s technology and maintaining its financial health.

Learn more: